Increased incidence of cutaneous squamous cell carcinoma in lung transplant recipients taking long-term voriconazole
Voriconazole is commonly prescribed for treatment of fungal infections in lung transplant recipients. Typically patients are treated for several weeks with this medication. This retrospective study of 120 lung transplant recipients compared the incidence of squamous cell carcinoma in patients with and without voriconazole use. Squamous cell carcinomas (SCC) developed in 39.5% of patients who received either prophylaxis or treatment with voriconazole, compared to 19.5% of patients who did not receive voriconazole. All 4 deaths related to metastatic SCC were previously treated with voriconazole. Prolonged courses of voriconazole may be associated with higher rates of SCC.